Sotatercept for pulmonary arterial hypertension
Treatments studied
Part of Lungs & breathing clinical trials.
This study tests a new medication called sotatercept for people with pulmonary arterial hypertension (PAH) who are already on at least two other PAH treatments. The goal is to see if adding sotatercept can improve symptoms and exercise ability.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a confirmed diagnosis of pulmonary arterial hypertension (PAH) from a right heart catheterization
- Your symptoms fall into WHO functional class II or III (some limitation in daily activities)
- You are currently on at least 2 PAH medications (or 1 if you cannot take the others) at the same doses for at least 60 days
- You are not pregnant or breastfeeding, and you agree to use effective birth control during the study
- You do not have certain other health conditions like severe liver disease, uncontrolled blood pressure, or recent heart problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether people with pulmonary arterial hypertension (PAH), a type of high blood pressure in the lungs, can safely stop taking the medication sotatercept after being on it for at least 6 months and doing well. It aims to see if those who stop can maintain their health without the drug.
This study tests a new treatment called sotatercept for people with pulmonary arterial hypertension (PAH), a condition where the blood vessels in the lungs are narrow, making the heart work harder. The goal is to see if this medicine can help improve symptoms and daily function.
This study looks at how a medication called sotatercept affects the blood vessels in the lungs over time. It aims to see if it can help improve how the heart and lungs work in people with pulmonary hypertension.
This Phase 2 trial tests sotatercept, a medicine that targets the blood-vessel changes in pulmonary arterial hypertension (PAH), in children. It may help improve how well the heart and lungs work by changing the underlying disease process.
This study tests a medicine called sotatercept to see if it can improve how the right side of your heart pumps in people with PAH. It may help you feel better and slow down the disease.
This trial tests a new combination of three medicines (including an experimental drug called sotatercept) for people recently diagnosed with PAH. The goal is to see if this early, powerful treatment works better than standard care in improving heart and lung function.
Hear when a new Pulmonary Artery Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.